Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits; Student group that ranked med schools over industry conflicts votes to accept pharma funding

Taking stock of the drug industry, from the lab to the medicine chest

June 5, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Yichuan Cao/Sipa USA via AP Images STAT+ | Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits The agreement caps a dispute that cast a spotlight on a strategy Gilead allegedly used to maximize revenues but at the expense of patients. By Ed Silverman STAT+ | Student group that ranked med schools over industry conflicts votes to accept pharma funding "This is a fundamental shift from the organization's core and long-standing value of being 'pharm-free,'" dozens of ASMA alumni complained. By Ed Silverman STAT+ | Eli Lilly's obesity drug Zepbound improved liver scarring in mid-stage MASH study Lilly's biggest competitor in the space, Novo Nordisk, is currently testing its obesity drug Wegovy in MASH in a Phase 3 trial. By Elaine Chen CDC and NIAID Finland to offer bird flu vaccine to select groups of people, a possible global first Mia Kontio, a health security official at the Finnish Institute for Health and Welfare, told STAT the country was waiting for 20,000 doses to arrive. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser